Genmab — Februar 2019
-
I don't think you should be focusing too much on the extra dose in the SC formulation - the direct cost is veryvery marginal compared to the product price, especially when we look ahead 12 months. At that point yearly revenue will be at +usd 3b and production volumes very high
-
nohope@ det lyder fornuftigt. kan godt forstå din frustration. selv havde jeg set det komme og derfor solgte jeg ud i morges ved åbningen. jeg er stadig ikke sikker på hvor vi er på vej hen. måske længere ned end tidligere ? ja jeg ved godt at det ikke løfter stemningen, men jeg er usikker på om den lange trend skal sende kursen ned under 700 (ja jeg mener det) !
-
delivery capacity, ease of use, use in maintenance setting etc will be driving sales
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind